Abstract
Risk of severe adverse events (AEs) during FP treatment can be significantly reduced through dose reduction in patients (pts) with dihydropyrimidine dehydrogenase (DPD) deficiency, the main FP metabolizing enzyme. Hence, in 2020 EMA stated that screening for DPD deficiency should be performed before FP treatment by DPYD genotyping, or by DPD phenotyping using plasma uracil (U) levels. Based on previous studies, pts with U >16 ng/ml are considered DPD deficient. However, a specific dosing strategy for these pts is missing.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
